Pfizer’s 2025 Super Bowl ad, which aired during the first quarter of the game, has quickly earned the title of the least popular commercial, sparking outrage across social media and the internet.
The ad, featuring a young boy who beats cancer, was clearly designed to tug at heartstrings and tout Pfizer’s commitment to fighting the disease.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
Latest Video
But instead, it has drawn widespread and ongoing backlash for what most people see as an exploitative and shameless attempt capitalize on the cancer epidemic caused by their mRNA gene therapy injections.
ADWEEK’s social listening data, which tracks the popularity of Super Bowl commercials, revealed that Pfizer’s ad was the most unpopular among all the commercials aired during the event.
Early data shows that the overwhelming majority of online mentions of Pfizer in the 24 hours following the airing of the ad have been negative.
Viewers are calling out the pharmaceutical giant for trying to play both sides—promoting itself as the savior of cancer patients while still being linked to a global vaccine rollout that has raised questions about its safety, side effects, and long-term health risks.
The cancer ad was cool until I saw it’s by Pfizer.
— Sonali, your friendly dentist🦷 (@chutneylife) February 9, 2025
Pfizer, which was under fire for rushing its vaccine into the market during a global crisis, is now facing the consequences of its earlier decisions.
As more people report experiencing adverse health effects from the vaccine, including the link to turbo cancer, Pfizer’s latest move to showcase itself as a champion in cancer research and treatment is not just tone-deaf but dangerously misleading.
When asked for a response, a Pfizer spokesperson provided the following in an email: “The Big Game unites millions, and Pfizer is seizing this moment to spark hope for the future of cancer care as we work to deliver eight breakthrough cancer treatments by 2030. It’s an opportunity to empower people to understand their risk and take action in the fight against cancer.”
On a larger scale, the Big Pharma giant has been dealing with rises and falls in public perception for years.
Figures from data analytics firm Morning Consult show U.S. consumer trust in Pfizer rose during the early days of the pandemic, but has declined since then, approaching pre-Covid levels.
In June 2024, Pfizer’s first global chief marketing officer, Drew Panayiotou, left the company after less than two years in the role. Under Panayiotou, last year Pfizer ran its first-ever Super Bowl ad, the notorious “Here’s to Science.”
Despite the massive drop in public trust, Pfizer has continued to make money on the back of its mRNA gene therapy products. Earlier this month, Pfizer reported it generated $63.6 billion in revenue during 2024, up 7% year-on-year.